582323-16-8 Usage
General Description
"Benzamide, N-(2-chloro-5-pyrimidinyl)-3,4-difluoro-" is a chemical compound recognized for its complex molecular structure. It belongs to the family of benzamides, a type of organic compound, and includes a pyrimidine ring in its structure - a heterocyclic aromatic organic compound similar to benzene and pyridine. The mention of 2-chloro signifies the presence of a chlorine atom in the structure, while 3,4-difluoro indicates two fluorine atoms. The precise properties, uses, and effects of this specific compound can vary and may be determined through research or laboratory usage, often involving applications in pharmaceuticals or agriculture. Its CAS number is 104777-68-9.
Check Digit Verification of cas no
The CAS Registry Mumber 582323-16-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,8,2,3,2 and 3 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 582323-16:
(8*5)+(7*8)+(6*2)+(5*3)+(4*2)+(3*3)+(2*1)+(1*6)=148
148 % 10 = 8
So 582323-16-8 is a valid CAS Registry Number.
582323-16-8Relevant articles and documents
N -pyridyl and pyrimidine benzamides as KCNQ2/Q3 potassium channel openers for the treatment of epilepsy
Amato, George,Roeloffs, Rosemarie,Rigdon, Greg C.,Antonio, Brett,Mersch, Theresa,McNaughton-Smith, Grant,Wickenden, Alan D.,Fritch, Paul,Suto, Mark J.
, p. 481 - 484 (2011/08/22)
A series of N-pyridyl benzamide KCNQ2/Q3 potassium channel openers were identified and found to be active in animal models of epilepsy and pain. The best compound 12 [ICA-027243, N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide] has an EC50 of 0.38 μM and is selective for KCNQ2/Q3 channels. This compound was active in several rodent models of epilepsy and pain but upon repeated dosing had a number of unacceptable toxicities that prevented further development. On the basis of the structure-activity relationships developed around 12, a second compound, 51, [N-(2-chloro-pyrimidin-5-yl)-3,4-difluoro- benzamide, ICA-069673], was prepared and advanced into a phase 1 clinical study. Herein, we describe the structure-activity relationships that led to the identification of compound 12 and to the corresponding pyrimidine 51.
